

# Armin Giese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6337819/publications.pdf>

Version: 2024-02-01

170  
papers

15,204  
citations

23567

58  
h-index

19190

118  
g-index

178  
all docs

178  
docs citations

178  
times ranked

14924  
citing authors

#	ARTICLE	IF	CITATIONS
1	Seizure prevalence in neurodegenerative diseases—a study of autopsy proven cases. <i>European Journal of Neurology</i> , 2022, 29, 12-18.	3.3	6
2	Blood $\beta$ -Synuclein and Neurofilament Light Chain During the Course of Prion Disease. <i>Neurology</i> , 2022, 10.1212/WNL.000000000200002.	1.1	11
3	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	12.8	34
4	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. <i>EBioMedicine</i> , 2022, 80, 104021.	6.1	26
5	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. <i>Lancet Neurology</i> , The, 2021, 20, 107-116.	10.2	62
6	Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety. <i>Journal of Neurology</i> , 2021, 268, 367-376.	3.6	9
7	Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. <i>Acta Neuropathologica</i> , 2021, 141, 323-325.	7.7	20
8	First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. <i>European Journal of Neurology</i> , 2021, 28, 1801-1811.	3.3	11
9	Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	3.9	22
10	The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. <i>Acta Neuropathologica Communications</i> , 2021, 9, 35.	5.2	11
11	Phenotypic diversity of genetic Creutzfeldt–Jakob disease: a histo-molecular-based classification. <i>Acta Neuropathologica</i> , 2021, 142, 707-728.	7.7	24
12	A Multi-Scale and Multi-Technique Approach for the Characterization of the Effects of Spatially Fractionated X-ray Radiation Therapies in a Preclinical Model. <i>Cancers</i> , 2021, 13, 4953.	3.7	4
13	[ $^{11}\text{C}$ ]MODAG-001—towards a PET tracer targeting $\beta$ -synuclein aggregates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1759-1772.	6.4	50
14	Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2020, 1862, 183064.	2.6	38
15	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4-Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
16	$^{11}\text{C}$ Radiolabeling of anle253b: a Putative PET Tracer for Parkinson's Disease That Binds to $\beta$ -Synuclein Fibrils in vitro and Crosses the Blood–Brain Barrier. <i>ChemMedChem</i> , 2020, 15, 411-415.	3.2	35
17	Targeting $\beta$ -synuclein by PD03 AFFITOPE <sup>®</sup> and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. <i>Translational Neurodegeneration</i> , 2020, 9, 38.	8.0	22
18	Clinical Conditions –Suggestive of Progressive Supranuclear Palsy—Diagnostic Performance. <i>Movement Disorders</i> , 2020, 35, 2301-2313.	3.9	22

#	ARTICLE	IF	CITATIONS
19	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	7.7	210
20	Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-qPCR. <i>FEBS Open Bio</i> , 2020, 10, 883-893.	2.3	6
21	Copathology in Progressive Supranuclear Palsy: Does It Matter?. <i>Movement Disorders</i> , 2020, 35, 984-993.	3.9	48
22	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105924.	1.4	3
23	Travel-associated neurological disease terminated in a postmortem diagnosed atypical HSV-1 encephalitis after high-dose steroid therapy – a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 150.	2.9	3
24	Binding of Metal-Ion-Induced Tau Oligomers to Lipid Surfaces Is Enhanced by GSK-3 $\beta$ -Mediated Phosphorylation. <i>ACS Chemical Neuroscience</i> , 2020, 11, 880-887.	3.5	8
25	Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. <i>PLoS ONE</i> , 2020, 15, e0231495.	2.5	11
26	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 67.	6.2	28
27	Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3815-3829.	3.5	60
28	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
29	Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression. <i>Scientific Reports</i> , 2019, 9, 9100.	3.3	8
30	Depopulation of dense $\alpha$ -synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. <i>Acta Neuropathologica</i> , 2019, 138, 575-595.	7.7	79
31	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
32	Protein-Drug Interactions in the Membrane: The Small Molecule Anle138b and its Binding to $\alpha$ -Synuclein Oligomers. <i>Biophysical Journal</i> , 2019, 116, 352a.	0.5	2
33	PATH-04. INFLUENCE OF INDIVIDUAL CpG METHYLATION STATUS OF THE MGMT PROMOTOR ON OUTCOME IN ADULT PATIENTS WITH GLIOBLASTOMA MULTIFORME RECEIVING ALKYLATING AGENT TREATMENT. <i>Neuro-Oncology</i> , 2019, 21, vi143-vi143.	1.2	0
34	The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers. <i>Scientific Reports</i> , 2019, 9, 19023.	3.3	16
35	Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. <i>European Journal of Cancer</i> , 2019, 107, 15-27.	2.8	30
36	Different Effects of $\alpha$ -Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1649-1659.	3.5	44

#	ARTICLE	IF	CITATIONS
37	Anle138b modulates $\alpha$ -synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 255-263.	3.9	72
38	Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 424-427.	1.9	31
39	Epilepsy surgery in the first months of life: a large type IIb focal cortical dysplasia causing neonatal drug-resistant epilepsy. <i>Epileptic Disorders</i> , 2019, 21, 122-127.	1.3	5
40	Regional pattern of microgliosis in sporadic Creutzfeldt-Jakob disease in relation to phenotypic variants and disease progression. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 574-589.	3.2	17
41	Photophysics of diphenyl-pyrazole compounds in solutions and $\alpha$ -synuclein aggregates. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 800-807.	2.4	10
42	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. <i>Neuro-Oncology</i> , 2018, 20, 279-288.	1.2	71
43	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 239-247.	1.9	89
44	The Small Molecule anle138b Shows Interaction with $\alpha$ -Synuclein Oligomers in Phospholipid Membranes. <i>Biophysical Journal</i> , 2018, 114, 560a.	0.5	2
45	Cell Type and Species-specific Patterns in Neuronal and Non-neuronal Methylomes of Human and Chimpanzee Cortices. <i>Cerebral Cortex</i> , 2018, 28, 3724-3739.	2.9	7
46	TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. <i>Journal of Neuro-Oncology</i> , 2018, 139, 671-678.	2.9	51
47	DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex. <i>Epigenetics and Chromatin</i> , 2018, 11, 41.	3.9	173
48	MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results. <i>Medical Oncology</i> , 2018, 35, 103.	2.5	2
49	The diphenylpyrazole compound anle138b blocks $A\beta$ channels and rescues disease phenotypes in a mouse model for amyloid pathology. <i>EMBO Molecular Medicine</i> , 2018, 10, 32-47.	6.9	63
50	Contrast enhancement as a prognostic factor in IDH1/2 mutant glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2029-2029.	1.6	0
51	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
52	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
53	Treatment with diphenylpyrazole compound anle138b/c reveals that $\alpha$ -synuclein protects melanoma cells from autophagic cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4971-E4977.	7.1	25
54	MR imaging differentiation of Fe <sup>2+</sup> and Fe <sup>3+</sup> based on relaxation and magnetic susceptibility properties. <i>Neuroradiology</i> , 2017, 59, 403-409.	2.2	36

#	ARTICLE	IF	CITATIONS
55	Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex. <i>EMBO Molecular Medicine</i> , 2017, 9, 716-731.	6.9	58
56	K27M midline gliomas display malignant progression by imaging and histology. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 458-462.	3.2	9
57	Immunoprofiling of glial tumours of the neurohypophysis suggests a common pituicytic origin of neoplastic cells. <i>Pituitary</i> , 2017, 20, 211-217.	2.9	26
58	Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. <i>PLoS ONE</i> , 2017, 12, e0188989.	2.5	11
59	The Differential Diagnosis and Treatment of Atypical Parkinsonism. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2016, 113, 61-9.	0.9	135
60	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. <i>Frontiers in Neuroscience</i> , 2016, 10, 99.	2.8	23
61	An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. <i>Acta Neuropathologica Communications</i> , 2016, 4, 120.	5.2	22
62	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. <i>Scientific Reports</i> , 2016, 6, 38737.	3.3	81
63	Effect of the Novel Amyloid Inhibitor $\alpha$ -145 on Aggregation of Islet Amyloid Polypeptide and how it is Modulated by Membranes. <i>Biophysical Journal</i> , 2016, 110, 420a.	0.5	0
64	Analysis of Conformational Stability of Abnormal Prion Protein Aggregates across the Spectrum of Creutzfeldt-Jakob Disease Prions. <i>Journal of Virology</i> , 2016, 90, 6244-6254.	3.4	29
65	Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 591-599.	2.9	28
66	Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 115-121.	2.2	72
67	Generation and deposition of A $\beta$ 243 by the virtually inactive presenilin $\epsilon$ 1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016, 8, 458-465.	6.9	60
68	Intracellular formation of $\beta$ -synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 76-82.	2.1	4
69	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	2.8	32
70	Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats. <i>Neurourology and Urodynamics</i> , 2016, 35, 464-470.	1.5	12
71	Quantifying prion disease penetrance using large population control cohorts. <i>Science Translational Medicine</i> , 2016, 8, 322ra9.	12.4	289
72	Interaction of $\beta$ -synuclein with biomembranes in Parkinson's disease - role of cardiolipin. <i>Progress in Lipid Research</i> , 2016, 61, 73-82.	11.6	73

#	ARTICLE	IF	CITATIONS
73	Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 408-414.	1.7	35
74	Age-Dependent Levels of 5-Methyl-, 5-Hydroxymethyl-, and 5-Formylcytosine in Human and Mouse Brain Tissues. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 12511-12514.	13.8	116
75	Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 295-301.	3.7	160
76	Dynamic <sup>18</sup> F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. <i>International Journal of Cancer</i> , 2015, 136, 2132-2145.	5.1	68
77	The Novel Inhibitor Anle145 Efficiently Inhibits Fibril Formation of Islet Amyloid Polypeptide (IAPP) and uses Distinctly Different Modes of Action in the Absence and Presence of Membranes. <i>Biophysical Journal</i> , 2015, 108, 256a.	0.5	0
78	Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to $\alpha$ -synuclein aggregates. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1884-1890.	2.4	52
79	Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 924-933.	1.7	10
80	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. <i>Acta Neuropathologica</i> , 2015, 130, 537-555.	7.7	157
81	The association of aphasia and right-sided motor impairment in corticobasal syndrome. <i>Journal of Neurology</i> , 2015, 262, 2241-2246.	3.6	9
82	Cysteine-Sparing CADASIL Mutations in <i>NOTCH3</i> Show Proaggregatory Properties In Vitro. <i>Stroke</i> , 2015, 46, 786-792.	2.0	46
83	Extracellular vesicle sorting of $\alpha$ -Synuclein is regulated by sumoylation. <i>Acta Neuropathologica</i> , 2015, 129, 695-713.	7.7	136
84	Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. <i>Acta Neuropathologica</i> , 2015, 130, 619-631.	7.7	58
85	Correlation of dynamic <sup>18</sup> F-FET-PET with IDH 1 mutation for prediction of outcome in anaplastic astrocytoma WHO $\geq$ III independently from tumor vascularisation.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2037-2037.	1.6	2
86	Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers. <i>PLoS ONE</i> , 2014, 9, e98906.	2.5	24
87	The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. <i>Movement Disorders</i> , 2014, 29, 1758-1766.	3.9	286
88	Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimer's disease. <i>Translational Psychiatry</i> , 2014, 4, e489-e489.	4.8	15
89	Scanning for Intensely Fluorescent Targets (SIFT) in the Study of Protein Aggregation at the Single-Particle Level. , 2014, , 167-176.		0
90	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. <i>Clinical Neurology and Neurosurgery</i> , 2014, 122, 113-115.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. <i>Acta Neuropathologica</i> , 2014, 127, 553-564.	7.7	17
92	Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. <i>Acta Neurochirurgica</i> , 2014, 156, 1427-1440.	1.7	51
93	Sequestration of latent TGF- $\beta$ 2 binding protein 1 into CADASIL-related Notch3-ECD deposits. <i>Acta Neuropathologica Communications</i> , 2014, 2, 96.	5.2	54
94	The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. <i>Acta Neuropathologica</i> , 2014, 127, 779-780.	7.7	103
95	Piperazine derivatives inhibit PrP/PrPres propagation in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 23-29.	2.1	9
96	Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 2532-2543.	2.6	120
97	Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues. <i>Acta Neuropathologica Communications</i> , 2013, 1, 44.	5.2	36
98	Presence of Phosphodiesterase Type 5 in the Spinal Cord and its Involvement in Bladder Outflow Obstruction Related Bladder Overactivity. <i>Journal of Urology</i> , 2013, 190, 1430-1435.	0.4	13
99	Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. <i>Acta Neuropathologica</i> , 2013, 125, 795-813.	7.7	327
100	Analyses of Protease Resistance and Aggregation State of Abnormal Prion Protein across the Spectrum of Human Prions. <i>Journal of Biological Chemistry</i> , 2013, 288, 27972-27985.	3.4	34
101	Adjunctive N-Acetyl-Cysteine in Treatment of Murine Pneumococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4825-4830.	3.2	9
102	Development and Implementation of a High-Throughput Compound Screening Assay for Targeting Disrupted ER Calcium Homeostasis in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e80645.	2.5	18
103	An Unusual Case of Ectopic ACTH Syndrome. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 63-67.	1.2	24
104	Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. <i>Acta Neuropathologica</i> , 2012, 124, 517-529.	7.7	184
105	Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. <i>Experimental Neurology</i> , 2012, 237, 470-476.	4.1	41
106	Polyphenolic compounds are novel protective agents against lipid membrane damage by $\beta$ -synuclein aggregates in vitro. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012, 1818, 2502-2510.	2.6	50
107	Synthesis of benzamide derivatives and their evaluation as antiprion agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 5001-5011.	3.0	10
108	Two Different Binding Modes of $\beta$ -Synuclein to Lipid Vesicles Depending on its Aggregation State. <i>Biophysical Journal</i> , 2012, 102, 1646-1655.	0.5	39



#	ARTICLE	IF	CITATIONS
109	Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with $\hat{1}\pm$ -synuclein at the single molecule level. <i>Molecular Neurodegeneration</i> , 2012, 7, 35.	10.8	60
110	Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by $\hat{1}\pm$ -Synuclein Oligomers in Lipid Membranes. <i>PLoS ONE</i> , 2012, 7, e42545.	2.5	75
111	Identification of Polyphenolic Compounds and Black Tea Extract as Potent Inhibitors of Lipid Membrane Destabilization by $\hat{A}\hat{1}^{242}$ Aggregates. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 767-779.	2.6	46
112	Single particle analysis of tau oligomer formation induced by metal ions and organic solvents. <i>Biochemical and Biophysical Research Communications</i> , 2011, 411, 190-196.	2.1	51
113	Comprehensive Neuropathologic Analysis of Genetic Prion Disease Associated With the E196K Mutation in PRNP Reveals Phenotypic Heterogeneity. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 192-200.	1.7	8
114	$\hat{1}\pm$ -Internexin in the Diagnosis of Oligodendroglial Tumors and Association With 1p/19q Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 970-978.	1.7	19
115	Generation of Ferric Iron Links Oxidative Stress to $\hat{1}\pm$ -Synuclein Oligomer Formation. <i>Journal of Parkinson's Disease</i> , 2011, 1, 205-216.	2.8	58
116	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced $\hat{1}\pm$ -synuclein oligomers. <i>Journal of Neurochemistry</i> , 2011, 117, 868-878.	3.9	60
117	Inhibition and disaggregation of $\hat{1}\pm$ -synuclein oligomers by natural polyphenolic compounds. <i>FEBS Letters</i> , 2011, 585, 1113-1120.	2.8	240
118	Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. <i>Acta Neuropathologica</i> , 2011, 121, 91-112.	7.7	134
119	Next-Generation Sequencing Reveals Regional Differences of the $\hat{1}\pm$ -Synuclein Methylation State Independent of Lewy Body Disease. <i>NeuroMolecular Medicine</i> , 2011, 13, 310-320.	3.4	61
120	Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis. <i>Journal of Neuroinflammation</i> , 2011, 8, 7.	7.2	26
121	From High-Throughput Cell Culture Screening to Mouse Model: Identification of New Inhibitor Classes against Prion Disease. <i>ChemMedChem</i> , 2011, 6, 1928-1937.	3.2	21
122	Diphenylpyrazole-Derived Compounds Increase Survival Time of Mice after Prion Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4774-4781.	3.2	12
123	Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. <i>Human Molecular Genetics</i> , 2011, 20, 3256-3265.	2.9	87
124	Divergent Molecular Effects of Desmin Mutations on Protein Assembly in Myofibrillar Myopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 415-424.	1.7	13
125	Inhibition of mitochondrial fusion by $\hat{1}\pm$ -synuclein is rescued by PINK1, Parkin and DJ-1. <i>EMBO Journal</i> , 2010, 29, 3571-3589.	7.8	431
126	Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 553-559.	1.5	40



#	ARTICLE	IF	CITATIONS
127	Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. <i>Brain</i> , 2010, 133, 3030-3042.	7.6	69
128	Converse modulation of toxic $\beta$ -synuclein oligomers in living cells by $N$ -benzylidene-benzohydrazide derivatives and ferric iron. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 461-466.	2.1	52
129	Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7756-7761.	7.1	98
130	CADASIL mutations enhance spontaneous multimerization of NOTCH3. <i>Human Molecular Genetics</i> , 2009, 18, 2761-2767.	2.9	72
131	Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. <i>Acta Neuropathologica</i> , 2009, 118, 659-671.	7.7	224
132	Increased $\beta$ -synuclein aggregation following limited cleavage by certain matrix metalloproteinases. <i>Experimental Neurology</i> , 2009, 215, 201-208.	4.1	80
133	Differential effects of prion particle size on infectivity in vivo and in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2008, 369, 924-928.	2.1	11
134	Characterization of Truncated Forms of Abnormal Prion Protein in Creutzfeldt-Jakob Disease. <i>Journal of Biological Chemistry</i> , 2008, 283, 30557-30565.	3.4	75
135	Single Particle Characterization of Iron-induced Pore-forming $\beta$ -Synuclein Oligomers. <i>Journal of Biological Chemistry</i> , 2008, 283, 10992-11003.	3.4	204
136	Different Species of $\beta$ -Synuclein Oligomers Induce Calcium Influx and Seeding. <i>Journal of Neuroscience</i> , 2007, 27, 9220-9232.	3.6	708
137	Identification of Anti-prion Compounds as Efficient Inhibitors of Polyglutamine Protein Aggregation in a Zebrafish Model. <i>Journal of Biological Chemistry</i> , 2007, 282, 9195-9203.	3.4	95
138	Repeated Peripheral Administrations of CpG Oligodeoxynucleotides Lead to Sustained CNS Immune Activation. <i>Immunopharmacology and Immunotoxicology</i> , 2007, 29, 413-424.	2.4	11
139	A refined method for molecular typing reveals that co-occurrence of PrPSc types in Creutzfeldt-Jakob disease is not the rule. <i>Laboratory Investigation</i> , 2007, 87, 1103-1112.	3.7	60
140	Generation of genuine prion infectivity by serial PMCA. <i>Veterinary Microbiology</i> , 2007, 123, 346-357.	1.9	51
141	Photo-induced crosslinking of prion protein oligomers and prions. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 67-77.	3.0	18
142	Chaperonin TRiC Promotes the Assembly of polyQ Expansion Proteins into Nontoxic Oligomers. <i>Molecular Cell</i> , 2006, 23, 887-897.	9.7	259
143	Unaltered prion protein cleavage in plasminogen-deficient mice. <i>NeuroReport</i> , 2006, 17, 527-530.	1.2	10
144	Cell-free formation of misfolded prion protein with authentic prion infectivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15818-15823.	7.1	50

#	ARTICLE	IF	CITATIONS
145	Mouse Brain Synaptosomes Accumulate Copper-67 Efficiently by Two Distinct Processes Independent of Cellular Prion Protein. <i>Journal of Molecular Neuroscience</i> , 2005, 27, 347-354.	2.3	27
146	Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets. <i>Journal of Virology</i> , 2005, 79, 7785-7791.	3.4	64
147	Automated PrPres amplification using indirect sonication. <i>Journal of Proteomics</i> , 2005, 63, 213-221.	2.4	13
148	Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein. <i>Biochemical and Biophysical Research Communications</i> , 2005, 326, 339-343.	2.1	29
149	Single particle analysis of manganese-induced prion protein aggregates. <i>Biochemical and Biophysical Research Communications</i> , 2005, 329, 1200-1207.	2.1	45
150	Single particle detection and characterization of synuclein co-aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 1202-1210.	2.1	47
151	Molecular Dynamics Simulations Indicate a Possible Role of Parallel $\beta^2$ -Helices in Seeded Aggregation of Poly-Gln. <i>Biophysical Journal</i> , 2005, 88, 2442-2451.	0.5	66
152	Effects of Different Experimental Conditions on the PrPSc Core Generated by Protease Digestion. <i>Journal of Biological Chemistry</i> , 2004, 279, 16797-16804.	3.4	118
153	Autocatalytic self-propagation of misfolded prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 12207-12211.	7.1	109
154	Effect of metal ions on de novo aggregation of full-length prion protein. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 1240-1246.	2.1	92
155	Decreased prion protein expression in human peripheral blood leucocytes from patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2001, 112, 658-662.	2.5	4
156	Prion Protein as Copper-Binding Protein at the Synapse. , 2001, 59, 17-30.		3
157	Current clinical diagnosis in Creutzfeldt-Jakob disease: Identification of uncommon variants. <i>Annals of Neurology</i> , 2000, 48, 323-329.	5.3	159
158	Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. <i>British Journal of Haematology</i> , 2000, 108, 488-495.	2.5	75
159	Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 5468-5473.	7.1	220
160	The Paraffin-Embedded Tissue Blot Detects PrPSc Early in the Incubation Time in Prion Diseases. <i>American Journal of Pathology</i> , 2000, 156, 51-56.	3.8	192
161	Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. <i>Annals of Neurology</i> , 1999, 46, 224-233.	5.3	1,314
162	Evidence of Presynaptic Location and Function of the Prion Protein. <i>Journal of Neuroscience</i> , 1999, 19, 8866-8875.	3.6	298

#	ARTICLE	IF	CITATIONS
163	Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. Lancet, The, 1998, 351, 1081-1085.	13.7	191
164	Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study. BMJ: British Medical Journal, 1998, 316, 577-582.	2.3	94
165	Role of Microglia in Neuronal Cell Death in Prion Disease. Brain Pathology, 1998, 8, 449-457.	4.1	209
166	The German FFI Cases. Brain Pathology, 1998, 8, 559-561.	4.1	7
167	Neuronal Degeneration and Cell Death in Prion Disease. , 1998, , 253-268.		3
168	The cellular prion protein binds copper in vivo. Nature, 1997, 390, 684-687.	27.8	1,170
169	Typing prion isoforms. Nature, 1997, 386, 232-233.	27.8	268
170	Neuronal Cell Death in Scrapie-Infected Mice Is Due to Apoptosis. Brain Pathology, 1995, 5, 213-221.	4.1	149